ArticleScientific reports2026
EpCAM-targeted ZIF-8 nanocarriers for enhanced doxorubicin delivery in cancer therapy: a promising approach for tumor-specific drug release.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the development of a targeted drug delivery system utilizing zeolitic imidazolate framework-8 (ZIF-8)-based nanocarriers functionalized with Epithelial Cell Adhesion Molecule (EpCAM) aptamers to enhance the therapeutic efficacy of Doxorubicin (DOX) against EpCAM-positive cancer cells. The inherent properties of ZIF-8, including its high surface area, structural stability, and pH-responsive degradation, make it an ideal vehicle for controlled drug release. The encapsulation of Doxorubicin within ZIF-8 nanocarriers, combined with surface modification using aptamers, is designed to direct DOX delivery specifically to tumor cells, thereby reducing off-target cytotoxicity. Our findings demonstrate that EpCAM-targeted, PEGylated ZIF-8 nanocarriers significantly improve the therapeutic efficacy of DOX while minimizing toxicity in non-cancerous cells. Furthermore, in vivo studies confirmed superior tumor suppression accompanied by reduced systemic toxicity. This research underscores the potential of EpCAM-modified ZIF-8 nanocarriers as a highly promising and innovative strategy for targeted cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.